Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Sara Kolell

Nurse Practitioner Oshkosh, WI Nurse Practitioner

NPI 1063694537 CMS profile 10440393

1855 S Koeller St, Oshkosh, WI 54902

Open in the dashboard

General payments

$279

5 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sara Kolell of Oshkosh, WI is reported in the CMS Open Payments database as having received $279 across 5 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 45th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $236 4
2022 General $43 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sara Kolell
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Sara Kolell were reported at $236. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Sara Kolell Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $43 $152 $48–$470 $149
2023 $0 $166 $54–$529 $160
2024 $0 $173 $55–$556 $164
2025 $236 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Dexcom, Inc. $141 2 payments
  2. Madrigal Pharmaceuticals $77 1 payment
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $43 1 payment
  4. Dynavax Technologies Corporation $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $279 5 payments
Products named General payments · program years 2022–2025
  1. DEXCOM G7 GSS (161) $113 1 payment
  2. DEXCOM STELO GLUCOSE BIOSENSOR $113 1 payment
  3. REZDIFFRA $77 1 payment
  4. OFEV $43 1 payment
  5. Dexcom G6 Transmitter $27 1 payment
  6. Heplisav-B $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 114 drugs

Part D claims

7,235

Median for Nurse Practitioner: 389

Drug cost

$394,953

Median for Nurse Practitioner: $21,885

Branded share of claims

16.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 69 $80,406
Jardiance Empagliflozin Brand 58 $62,050
Ozempic Semaglutide Brand 37 $37,605
Trulicity Dulaglutide Brand 36 $32,011
Rybelsus Semaglutide Brand 22 $26,308
Mounjaro Tirzepatide Brand 12 $12,190
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 73 $10,282
Symbicort Budesonide/Formoterol Fumarate Brand 18 $9,380
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 24 $7,849
Levothyroxine Sodium Generic 406 $6,146

The 10 drugs with the highest cost, of 114 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$35,038

Of which drugs: $5,862

Medicare patients

142

Average age 74

Services billed

783

96 women, 46 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 49%
Diabetes 30%
Ischemic heart disease 25%
Chronic kidney disease 25%
Osteoporosis 19%
COPD 17%
Depression 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 13 13 $1,044

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

5 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record